dc.creator | Bogdanos, D. P. | en |
dc.creator | Lenzi, M. | en |
dc.creator | Okamoto, M. | en |
dc.creator | Rigopoulou, E. I. | en |
dc.creator | Muratori, P. | en |
dc.creator | Ma, Y. | en |
dc.creator | Muratori, L. | en |
dc.creator | Tsantoulas, D. | en |
dc.creator | Mieli-Vergani, G. | en |
dc.creator | Bianchi, F. B. | en |
dc.creator | Vergani, D. | en |
dc.date.accessioned | 2015-11-23T10:23:56Z | |
dc.date.available | 2015-11-23T10:23:56Z | |
dc.date.issued | 2004 | |
dc.identifier.issn | 3946320 | |
dc.identifier.uri | http://hdl.handle.net/11615/26328 | |
dc.description.abstract | Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope. Molecular mimicry and immunological cross-reactivity between CYP2D6252-271, HCV polyprotein and the infected cell protein 4 (ICP4) of herpes simplex virus type 1 (HSV-1) have been suggested as triggers for the induction of LKM1, but reactivity and cross-reactivity to the relevant sequences have not been investigated experimentally. CYP2D6252-271 and its viral homologues were constructed and tested by ELISA in the sera of 46 chronically infected HCV patients, 23 of whom were LKM1 positive. Reactivity to the E1 HCV and ICP4 HSV1 mimics was frequently found in HCV infected patients irrespectively of their LKM1 status; viral/self cross-reactivity (as indicated by inhibition studies), however, was present in the only 2 of the 23 LKM1 seropositive HCV patients, who possessed the HLA allotype B51. Our results indicate that in HCV infected patients virus/self cross-reactivity is dependent on a specific immunogenetic background, a finding awaiting confirmation by studies in larger series of patients. | en |
dc.source | International Journal of Immunopathology and Pharmacology | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-5444251837&partnerID=40&md5=62c53fe37aaf44fe9516b2e60da200a0 | |
dc.subject | Hepatitis C virus | en |
dc.subject | HLA B51 | en |
dc.subject | Immunological cross-reactivity | en |
dc.subject | autoantibody | en |
dc.subject | B lymphocyte antigen | en |
dc.subject | cell protein | en |
dc.subject | cytochrome P450 2D6 | en |
dc.subject | cytochrome P450 2D6[252-271] | en |
dc.subject | epitope | en |
dc.subject | HLA B51 antigen | en |
dc.subject | infected cell protein 4 | en |
dc.subject | liver kidney microsome antibody | en |
dc.subject | liver kidney microsome autoantibody type 1 | en |
dc.subject | microsome antibody | en |
dc.subject | polyprotein | en |
dc.subject | unclassified drug | en |
dc.subject | virus protein | en |
dc.subject | anti liver kidney microsome antibody | en |
dc.subject | anti-liver kidney microsome antibody | en |
dc.subject | hepatitis C antibody | en |
dc.subject | HLA B antigen | en |
dc.subject | HLA Bw51 | en |
dc.subject | HLA-Bw51 | en |
dc.subject | peptide fragment | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | allotype | en |
dc.subject | amino acid sequence | en |
dc.subject | antibody production | en |
dc.subject | antigen binding | en |
dc.subject | article | en |
dc.subject | autoimmune hepatitis | en |
dc.subject | autoimmune hepatitis type 2 | en |
dc.subject | autoimmunity | en |
dc.subject | clinical article | en |
dc.subject | controlled study | en |
dc.subject | cross reaction | en |
dc.subject | enzyme linked immunosorbent assay | en |
dc.subject | female | en |
dc.subject | hepatitis C | en |
dc.subject | Herpes simplex virus 1 | en |
dc.subject | HLA typing | en |
dc.subject | human | en |
dc.subject | immunogenetics | en |
dc.subject | immunoreactivity | en |
dc.subject | inhibition kinetics | en |
dc.subject | kidney microsome | en |
dc.subject | liver microsome | en |
dc.subject | male | en |
dc.subject | molecular mimicry | en |
dc.subject | priority journal | en |
dc.subject | serology | en |
dc.subject | virus cross reaction | en |
dc.subject | virus immunity | en |
dc.subject | antibody combining site | en |
dc.subject | blood | en |
dc.subject | genetics | en |
dc.subject | genotype | en |
dc.subject | histocompatibility test | en |
dc.subject | immunology | en |
dc.subject | kidney | en |
dc.subject | metabolism | en |
dc.subject | middle aged | en |
dc.subject | molecular genetics | en |
dc.subject | Autoantibodies | en |
dc.subject | Binding Sites, Antibody | en |
dc.subject | Cross Reactions | en |
dc.subject | Cytochrome P-450 CYP2D6 | en |
dc.subject | Hepacivirus | en |
dc.subject | Hepatitis C Antibodies | en |
dc.subject | Hepatitis C, Chronic | en |
dc.subject | Histocompatibility Testing | en |
dc.subject | HLA-B Antigens | en |
dc.subject | Humans | en |
dc.subject | Microsomes, Liver | en |
dc.subject | Molecular Sequence Data | en |
dc.subject | Peptide Fragments | en |
dc.title | Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus-infected patients is associated with the possession of HLA B51 | en |
dc.type | journalArticle | en |